PMID- 33894103 OWN - NLM STAT- MEDLINE DCOM- 20210819 LR - 20211022 IS - 1478-3231 (Electronic) IS - 1478-3223 (Print) IS - 1478-3223 (Linking) VI - 41 IP - 9 DP - 2021 Sep TI - Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. PG - 2059-2067 LID - 10.1111/liv.14905 [doi] AB - BACKGROUND: Data concerning the impact of hepatitis C virus (HCV) cure on type 2 diabetes mellitus (T2DM) are controversial. The aim of the study was to evaluate the effects of anti-HCV direct-acting antiviral (DAA) treatments on long-term glucose control in HCV/T2DM patients with chronic hepatitis C (CHC) or with cirrhosis. METHODS: One hundred and eighty-two consecutive HCV/T2DM patients who achieved a viral clearance by DAA treatment were enrolled. Seventy or 182 of them had CHC, and 112 had cirrhosis. Clinical, biochemical and instrumental parameters were recorded at baseline and at 48, 96 and 120 weeks (48w, 96w and 120w, respectively) after stopping DAA therapy. RESULTS: At baseline, the overall study population had a mean of glycated haemoglobin (HbA1c) value of 7.2% (ranging from 5 to 11.2), without any significant differences between CHC and cirrhosis [7.1 and 7.2, respectively]. Evaluation over time of HbA1c variations showed a significant improvement of glucose control at all post-treatment time points compared with baseline in CHC patients (P = .001). In cirrhotic patients, a significant decrease of HbA1c levels was only found when comparing HbA1c values between baseline and 48w time-point (P = .001), whereas this improvement disappeared at both 98w and 120w (P = .8 and P = .3, respectively). Multivariate logistic regression analysis showed that patients with chronic hepatitis have a 2.5 (CI 1.066-5.945) times greater chance of achieving an improvement of glycaemic values than patients with liver cirrhosis (P = .035). CONCLUSION: DAA-based HCV cure induces a significant and persistent amelioration of glycaemic control in HCV/diabetic patients with chronic hepatitis, whereas cirrhotic HCV/diabetic subjects have only a transient benefit from the virus elimination. CI - (c) 2021 The Authors. Liver International published by John Wiley & Sons Ltd. FAU - Cacciola, Irene AU - Cacciola I AUID- ORCID: 0000-0001-7721-6799 AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Russo, Giuseppina AU - Russo G AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Diabetology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Filomia, Roberto AU - Filomia R AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Pitrone, Concetta AU - Pitrone C AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Caccamo, Gaia AU - Caccamo G AUID- ORCID: 0000-0001-9755-5990 AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Giandalia, Annalisa AU - Giandalia A AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Diabetology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Alibrandi, Angela AU - Alibrandi A AD - Department of Economics Unit of Statistical and Mathematical Science of Messina, University of Messina, Messina, Italy. FAU - Stella Franze, Maria AU - Stella Franze M AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Porcari, Serena AU - Porcari S AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Maimone, Sergio AU - Maimone S AUID- ORCID: 0000-0002-0823-1642 AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Saitta, Carlo AU - Saitta C AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Squadrito, Giovanni AU - Squadrito G AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Internal Medicine, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. FAU - Raimondo, Giovanni AU - Raimondo G AUID- ORCID: 0000-0003-3112-8587 AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Division of Medicine and Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210526 PL - United States TA - Liver Int JT - Liver international : official journal of the International Association for the Study of the Liver JID - 101160857 RN - 0 (Antiviral Agents) SB - IM MH - Antiviral Agents/therapeutic use MH - *Diabetes Mellitus, Type 2/complications/drug therapy MH - Glycemic Control MH - Hepacivirus MH - *Hepatitis C/drug therapy MH - *Hepatitis C, Chronic/complications/drug therapy MH - Humans MH - Liver Cirrhosis/drug therapy PMC - PMC8506140 OTO - NOTNLM OT - DAA therapies OT - HCV-related cirrhosis OT - chronic hepatitis C OT - glycated haemoglobin OT - type 2 diabetes mellitus COIS- The authors declare they have no conflict of interest. EDAT- 2021/04/25 06:00 MHDA- 2021/08/20 06:00 PMCR- 2021/10/12 CRDT- 2021/04/24 17:06 PHST- 2021/04/07 00:00 [revised] PHST- 2020/09/17 00:00 [received] PHST- 2021/04/15 00:00 [accepted] PHST- 2021/04/25 06:00 [pubmed] PHST- 2021/08/20 06:00 [medline] PHST- 2021/04/24 17:06 [entrez] PHST- 2021/10/12 00:00 [pmc-release] AID - LIV14905 [pii] AID - 10.1111/liv.14905 [doi] PST - ppublish SO - Liver Int. 2021 Sep;41(9):2059-2067. doi: 10.1111/liv.14905. Epub 2021 May 26.